Vaishali Pharma Limited

Founded in 2008 and headquartered in Maharashtra, India.

2008 | Mumbai, Maharashtra (India) | Active
Last Updated:

Vaishali Pharma Profile

Key Indicators

  • Authorised Capital ₹ 22.00 Cr
  • Paid Up Capital ₹ 13.05 Cr
  • Company Age 16 Year, 10 Months
  • Last Filing with ROC 31 Mar 2024
  • Open Charges ₹ 17.01 Cr
  • Satisfied Charges ₹ 15.12 Cr
  • Revenue Growth 39.63%
  • Profit Growth 284.58%
  • Ebitda 160.36%
  • Net Worth 17.56%
  • Total Assets -5.22%

About Vaishali Pharma

Vaishali Pharma Limited (VPL) is a leading Public Limited Indian Non-Government Company incorporated in India on 25 April 2008 and has a history of 16 years and ten months. Its registered office is in Mumbai, Maharashtra, India.

It is listed on the National Stock Exchange(NSE) under the ticker symbol VAISHALI.

The Corporate was formerly known as Vaishali Pharma Private Limited. The Company is engaged in the Pharma Industry.

The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 22.00 Cr and a paid-up capital of Rs 13.05 Cr.

The company currently has active open charges totaling ₹17.01 Cr. The company has closed loans amounting to ₹15.12 Cr, as per Ministry of Corporate Affairs (MCA) records.

The Key Managerial Personnel (KMP) at Vaishali Pharma Limited India are Hemant Pathak as Ceo, Vishwa Mekhia as Company Secretary, and Ratnesh Singh as Cfo. Atul Vasani, Jagruti Vasani, Pratik Jakhelia, and Four other members serve as directors at the Company.

Company Details

  • Location

    Mumbai, Maharashtra, India

  • Telephone

    +91-XXXXXXXXXX

  • Email Address

  • Website

  • Social Media

Corporate Identity Details

  • CIN/LLPIN

    L52310MH2008PLC181632

  • Company No.

    181632

  • Stock Symbol

    NSE : VAISHALI

  • Company Classification

    Public Limited Indian Non-Government Company

  • Incorporation Date

    25 Apr 2008

  • Date of AGM

    27 Sep 2024

  • Date of Balance Sheet

    31 Mar 2024

  • Listing Status

    Listed

  • ROC Code

    Roc Mumbai

Industry

Pharma

What products or services does Vaishali Pharma Limited offer?

Vaishali Pharma Limited offers a wide range of products and services, including Multivitamin Tablets & Capsules, Multivitamin Gummy, Calcium Supplements, Calcium Gummies, Vitamin Tablets & Capsules, Vitamin Effervescent Tablet, Nutritional Supplements, L-Arginine Capsules, Calcium Tablet, Calcium Citrate and Vitamin D3 Tablet.

Who are the key members and board of directors at Vaishali Pharma?

Executive Team (4)

NameDesignationAppointment DateStatus
Atul Vasani Country flag representing In Managing Director25-Apr-2008Current
Hemant Pathak CEO26-May-2020Current
Vishwa Mekhia Company Secretary20-Dec-2021Current
Ratnesh Singh Country flag representing In CFO25-May-2017Current

Board Members (6)

NameDesignationAppointment DateStatus
Jagruti Vasani Country flag representing In Whole-Time Director 12-Nov-2009Current
Pratik Jakhelia Country flag representing In Director 10-Jul-2021Current
Dewansh Vasani Country flag representing In Director 26-Apr-2018Current
Bhaveshkumar Upadhyay Country flag representing In Additional Director 03-Oct-2024Current
Ashvin Ganatra Country flag representing In Director 31-Dec-2019Current
Manish Ved Country flag representing In Director 31-Dec-2019Current

Financial Performance of Vaishali Pharma.

Vaishali Pharma Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 39.63% increase. The company also saw a substantial improvement in profitability, with a 284.58% increase in profit. The company's net worth Soared by an impressive increase of 17.56%.

Vaishali Pharma revenue growth over time
Vaishali Pharma profit and loss trends over time
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023)YOY Growth
(FY 2022)(FY 2021)(FY 2020)(FY 2019)
Total Revenue
39.63%
Revenue from Operations
41.00%
Total Assets
-5.22%
Profit or Loss
284.58%
Net Worth
17.56%
EBITDA
160.36%

What is the Ownership and Shareholding Structure of Vaishali Pharma?

In 2022, Vaishali Pharma had a promoter holding of 26.74% and a public holding of 73.26%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Indicator graph

Charges (Loans)

Open Charges

₹17.01 Cr

Satisfied Charges

₹15.12 Cr

Charges Breakdown by Lending Institutions

  • Others : 15.26 Cr
  • L&T Housing Finance Limited : 1.75 Cr

Latest Charge Details

DateLenderAmountStatus
30 Sep 2020Others₹2.60 MOpen
05 Jan 2019Others₹3.00 CrOpen
31 Jan 2015L&T Housing Finance Limited₹1.75 CrOpen
10 Oct 2013Others₹12.00 CrOpen
29 Sep 2020Others₹8.58 MSatisfied

How Many Employees Work at Vaishali Pharma?

Vaishali Pharma has a workforce of 15 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee growth trends for Vaishali Pharma Limited

Deals i

Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Vaishali Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vaishali Pharma's trajectory.

Rating

Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts

Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Latest Updates, News, and FAQs on Vaishali Pharma

Recent activity within the organization

  • Director Appointment

    Bhaveshkumar Popatlal Upadhyay was appointed as a Additional Director was appointed as a Additional Director on 03 Oct 2024 & has been associated with this company since 5 months 5 days .

  • Annual General Meeting

    Vaishali Pharma Limited last Annual general meeting of members was held on 27 Sep 2024 as per latest MCA records.

  • Balance Sheet

    Vaishali Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai.

  • Charges

    A charge with Others of Rs. 12.00 Cr registered on 10 Oct 2013 with Charge ID 10460225 was modified on 24 Mar 2023.

  • Charges

    A charge registered on 09 Mar 2017 via Charge ID 100084949 with Others was fully satisfied on 27 Jul 2022.

  • Director Appointment

    Vishwa Bipinbhai Mekhia was appointed as a Company Secretary was appointed as a Company Secretary on 20 Dec 2021 & has been associated with this company since 3 years 2 months .

Recent News, Updates & Announcement

Frequently asked questions

  • What is the Incorporation or founding date of Vaishali Pharma Limited?

    Vaishali Pharma Limited was incorporated on 25 Apr 2008.

  • What is authorized share capital and paid-up capital of Vaishali Pharma Limited?

    The authorized share capital of Vaishali Pharma Limited is ₹ 22.00 Cr and paid-up capital is ₹ 13.05 Cr.

  • Who are the current board members & directors of Vaishali Pharma Limited?

    Currently 10 directors are associated with Vaishali Pharma Limited.

    • Atul Arvind Vasani
    • Jagruti Atul Vasani
    • Pratik Vikram Jakhelia
    • Dewansh Ajay Vasani
    • Bhaveshkumar Popatlal Upadhyay
    • Ashvin Jamnadas Ganatra
    • Manish Bhagwandas Ved
    • Hemant Damodar Pathak
    • Vishwa Bipinbhai Mekhia
    • Ratnesh Raghunath Singh

  • What is the registered address of Vaishali Pharma Limited?

    As per Ministry of Corporate Affairs (Mca), the registered address of Vaishali Pharma Limited is 706 To 709 7Th Fl Aravali Busines Center R. C. Patel Road Off Sodawala Lane, Bor Ivali West India, Mumbai, Maharashtra, 400092.

  • What is the corporate identification number (CIN) and company number of Vaishali Pharma Limited?

    The corporate identification number (CIN) of Vaishali Pharma Limited is L52310MH2008PLC181632 and the company number is 181632 as per Ministry of Corporate Affairs (MCA).

  • Is Vaishali Pharma Limited registered with any stock exchange in India?

    Yes, Vaishali Pharma Limited is registered on National Stock Exchange (NSE).

  • What is the official website of Vaishali Pharma Limited?

    The Official website of Vaishali Pharma Limited is https://www.vaishalipharma.com

  • What has been the recent revenue trend for Vaishali Pharma Limited?

    According to the financial reports for the fiscal year 2022, the revenue trend for Vaishali Pharma Limited has risen by 39.63%.

  • How many employees does Vaishali Pharma Limited currently have?

    As Per 2022 financial reports, 15 employees are currently employed by Vaishali Pharma Limited.

  • What change has been observed in the net worth of Vaishali Pharma Limited, and by what percentage?

    The financial reports for the fiscal year 2022 indicates that The net worth of Vaishali Pharma Limited has experienced an upsurge of 17.56%.

  • What are the total open charges for Vaishali Pharma Limited?

    As per the financial statements for fiscal Year 2022, The total open charges for Vaishali Pharma Limited amount to ₹ 17.01 Cr.

  • When was the last Balance Sheet of Vaishali Pharma Limited filed with the ROC?

    The most recent Balance Sheet for Vaishali Pharma Limited was filed with the ROC on 31 Mar 2024.

People also Viewed

Similar Companies Based on Drug Formulation & Development